<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934555</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000319</org_study_id>
    <nct_id>NCT02934555</nct_id>
  </id_info>
  <brief_title>Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest</brief_title>
  <official_title>Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaneka Medical America LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of ubiquinol as a &quot;metabolic resuscitator&quot; in post-cardiac arrest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac arrest (CA) occurs in more than 400,000 patients in the United States each year with&#xD;
      an estimated mortality of greater than 90%. The majority of patients who are resuscitated&#xD;
      from CA will succumb to the neurologic morbidity associated with the post-CA syndrome and&#xD;
      ischemic-reperfusion injury. Currently, there are no pharmacologic agents known to offer&#xD;
      survival benefit or to prevent devastating neurologic injury in post-CA patients.&#xD;
&#xD;
      A potential therapeutic target following ischemia-reperfusion injury is mitochondrial&#xD;
      function in the injured cell and/or reduction of oxygen free radicals. Coenzyme Q10 (CoQ10)&#xD;
      is an essential mitochondrial co-factor and free radical scavenger that has been proposed as&#xD;
      a neuroprotective agent in various neurodegenerative disorders as well as a cardioprotective&#xD;
      agent. CoQ10 have furthermore shown exciting preliminary results as a potential therapy in&#xD;
      post-CA.&#xD;
&#xD;
      In order to test the effects of ubiquinol as a &quot;metabolic resuscitator&quot; in post-CA patients&#xD;
      and to provide additional preliminary data for a large-scale clinical trial, the&#xD;
      investigators are conducting a randomized, double-blind, place-controlled trial of ubiquinol&#xD;
      in post-CA patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2, 2019</completion_date>
  <primary_completion_date type="Actual">May 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coenzyme Q10 Plasma Levels</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Total (oxidized and reduced form) coenzyme Q10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decreased Neurological Injury</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Neuron Specific Enolase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Oxygen Consumption</measure>
    <time_frame>At 24 hours</time_frame>
    <description>Cellular (peripheral blood mononuclear cells) oxygen consumption measured with the XFe24 Extracellular Flux Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Oxygen Consumption</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>VO2 measured using a Compact Anesthesia monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At hospital discharge, an average of 14 days</time_frame>
    <description>In-hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Favorable Neurological Outcome</measure>
    <time_frame>At hospital discharge, an average of 14 days</time_frame>
    <description>Favorable Neurological Outcome as measured by the Cerebral Performance Category (CPC 1-2) score. A CPC score of 1 (mild or no neurological deficit) or 2 (moderate disability) was defined as a favorable neurological outcome. A CPC score of 3 (severe disability), 4 (vegetative state), or 5 (death) was defined as an unfavourable neurological outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ubiquinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ubiquinol</intervention_name>
    <description>300 mg Ubiquinol (3 mL liquid Ubiquinol).</description>
    <arm_group_label>Ubiquinol</arm_group_label>
    <other_name>CoQ10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ensure</intervention_name>
    <description>50 mL Ensure</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Ubiquinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (â‰¥ 18 years)&#xD;
&#xD;
          -  Cardiac arrest defined by cessation of pulse requiring chest compressions&#xD;
&#xD;
          -  Not following commands after ROSC&#xD;
&#xD;
          -  Admission to the ICU&#xD;
&#xD;
          -  Naso/orogastric tube&#xD;
&#xD;
          -  Ability to receive enteral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Protected populations (pregnant women, prisoners, the intellectual disabled)&#xD;
&#xD;
          -  Current CoQ10 supplementation&#xD;
&#xD;
          -  Anticipated death within 24 hours&#xD;
&#xD;
          -  &gt; 12 hours from ROSC to estimated randomization&#xD;
&#xD;
          -  Jejunostomy tube (J-tube)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Donnino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <results_first_submitted>December 20, 2020</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2021</results_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Donnino</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT02934555/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
        </group>
        <group group_id="P2">
          <title>Ubiquinol</title>
          <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
        </group>
        <group group_id="B2">
          <title>Ubiquinol</title>
          <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="57" upper_limit="79"/>
                    <measurement group_id="B2" value="60" lower_limit="46" upper_limit="69"/>
                    <measurement group_id="B3" value="62" lower_limit="52" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Shock</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Shock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-shock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coenzyme Q10 Plasma Levels</title>
        <description>Total (oxidized and reduced form) coenzyme Q10</description>
        <time_frame>Up to 72 hours</time_frame>
        <population>Blood samples were not available on all participants at all time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
          <group group_id="O2">
            <title>Ubiquinol</title>
            <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Coenzyme Q10 Plasma Levels</title>
          <description>Total (oxidized and reduced form) coenzyme Q10</description>
          <population>Blood samples were not available on all participants at all time-points.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" lower_limit="120" upper_limit="267"/>
                    <measurement group_id="O2" value="207" lower_limit="125" upper_limit="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" lower_limit="94" upper_limit="208"/>
                    <measurement group_id="O2" value="441" lower_limit="215" upper_limit="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="85" upper_limit="299"/>
                    <measurement group_id="O2" value="615" lower_limit="286" upper_limit="817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" lower_limit="102" upper_limit="169"/>
                    <measurement group_id="O2" value="554" lower_limit="380" upper_limit="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decreased Neurological Injury</title>
        <description>Neuron Specific Enolase levels</description>
        <time_frame>Up to 72 hours</time_frame>
        <population>Blood samples were not available on all participants at all time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
          <group group_id="O2">
            <title>Ubiquinol</title>
            <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Decreased Neurological Injury</title>
          <description>Neuron Specific Enolase levels</description>
          <population>Blood samples were not available on all participants at all time-points.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="5.9" upper_limit="10.7"/>
                    <measurement group_id="O2" value="9.2" lower_limit="6.7" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="4.3" upper_limit="19.1"/>
                    <measurement group_id="O2" value="16.8" lower_limit="9.5" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.9" upper_limit="9.2"/>
                    <measurement group_id="O2" value="12.6" lower_limit="4.3" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="4.0" upper_limit="14.4"/>
                    <measurement group_id="O2" value="14.4" lower_limit="4.0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular Oxygen Consumption</title>
        <description>Cellular (peripheral blood mononuclear cells) oxygen consumption measured with the XFe24 Extracellular Flux Analyzer</description>
        <time_frame>At 24 hours</time_frame>
        <population>Cellular oxygen consumption was measured in a subset of the total cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
          <group group_id="O2">
            <title>Ubiquinol</title>
            <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Oxygen Consumption</title>
          <description>Cellular (peripheral blood mononuclear cells) oxygen consumption measured with the XFe24 Extracellular Flux Analyzer</description>
          <population>Cellular oxygen consumption was measured in a subset of the total cohort.</population>
          <units>mL/min/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal OCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="5.5" upper_limit="9.0"/>
                    <measurement group_id="O2" value="6.5" lower_limit="3.7" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal OCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="16.1" upper_limit="34.5"/>
                    <measurement group_id="O2" value="18.0" lower_limit="10.8" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Oxygen Consumption</title>
        <description>VO2 measured using a Compact Anesthesia monitor</description>
        <time_frame>Up to 48 hours</time_frame>
        <population>Global oxygen consumption was measured in a subset of the total cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
          <group group_id="O2">
            <title>Ubiquinol</title>
            <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Oxygen Consumption</title>
          <description>VO2 measured using a Compact Anesthesia monitor</description>
          <population>Global oxygen consumption was measured in a subset of the total cohort.</population>
          <units>mL/min/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.6" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.0" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="3.0" upper_limit="3.6"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.9" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.9" upper_limit="4.8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.9" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>In-hospital mortality</description>
        <time_frame>At hospital discharge, an average of 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
          <group group_id="O2">
            <title>Ubiquinol</title>
            <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>In-hospital mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Favorable Neurological Outcome</title>
        <description>Favorable Neurological Outcome as measured by the Cerebral Performance Category (CPC 1-2) score. A CPC score of 1 (mild or no neurological deficit) or 2 (moderate disability) was defined as a favorable neurological outcome. A CPC score of 3 (severe disability), 4 (vegetative state), or 5 (death) was defined as an unfavourable neurological outcome.</description>
        <time_frame>At hospital discharge, an average of 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
          <group group_id="O2">
            <title>Ubiquinol</title>
            <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Favorable Neurological Outcome</title>
          <description>Favorable Neurological Outcome as measured by the Cerebral Performance Category (CPC 1-2) score. A CPC score of 1 (mild or no neurological deficit) or 2 (moderate disability) was defined as a favorable neurological outcome. A CPC score of 3 (severe disability), 4 (vegetative state), or 5 (death) was defined as an unfavourable neurological outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrolment until hospital discharge.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
        </group>
        <group group_id="E2">
          <title>Ubiquinol</title>
          <description>300 mg of Ubiquinol mixed with 50 mL of Ensure (a dietary supplement) every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Donnino</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>6177542882</phone>
      <email>mdonnino@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

